nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

03.04.2018 | Review – Cancer Research

Role of natural killer cells in lung cancer

verfasst von: Ozge Nur Aktaş, Ayşe Bilge Öztürk, Baran Erman, Suat Erus, Serhan Tanju, Şükrü Dilege

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

One of the key immune cells involved in the pathogenesis of lung cancer is natural killer (NK) cells and these cells are novel targets for therapeutic applications in lung cancer. The purpose of this review is to summarize the current literature on lung cancer pathogenesis with a focus on the interaction between NK cells and smoking, how these factors are related to the pathogenesis of lung cancer and how NK cell-based immunotherapy effect lung cancer survival.

Methods

The relevant literature from PubMed and Medline databases is reviewed in this article.

Results

The cytolytic potential of NK cells are reduced in lung cancer and increasing evidence suggests that improving NK cell functioning may induce tumor regression. Recent clinical trials on NK cell-based novel therapies such as cytokines including interleukin (IL)-15, IL-12 and IL-2, NK-92 cell lines and allogenic NK cell immunotherapy showed promising results with less adverse effects on the lung cancer survival.

Conclusions

The NK cell targeting strategy has not yet been approved for lung cancer treatment. More clinical studies focusing on the role of NK cells in lung cancer pathogenesis are warranted to develop novel NK cell-based therapeutic approaches for the treatment of lung cancer.

Al Omar SY, Marshall E, Middleton D, Christmas SE (2011) Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology 133(1):94–104CrossRefPubMedPubMedCentral

Andreoli C, Bassi A, Gregg EO, Nunziata A, Puntoni R, Corsini E (2015) Effects of cigarette smoking on circulating leukocytes and plasma cytokines in monozygotic twins. Clin Chem Lab Med 53(1):57–64CrossRefPubMed

Anton-Culver H, Chang J, Bray F, Znaor A, Stevens L, Eser S et al (2016) Cancer burden in four countries of the Middle East Cancer Consortium (Cyprus; Jordan; Israel; Izmir Turkey) with comparison to the United States surveillance; epidemiology and end results program. Cancer Epidemiol 44:195–202CrossRefPubMed

Bauer S et al (1999) Activation of natural killer cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–730CrossRefPubMed

Boutet P et al (2009) Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme regulates proteolytic shedding of the MHC class I‑related chain B protein. J Immunol 182:49–53CrossRefPubMed

Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G (2008) Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer 112(4):863–875CrossRefPubMed

Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100(7):4120–4125CrossRefPubMedPubMedCentral

Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640CrossRefPubMed

Cui F, Ji J, Lv H, Qu D, Yu C, Yang Y, Xu Y (2013) Immune responsiveness in a mouse model of combined adoptive immunotherapy with NK and dendritic cells. J Cancer Res Ther 9(Suppl):S162–S168PubMed

De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117:365–373CrossRefPubMed

Deniz G, van de Veen W, Akdis M (2013) Natural killer cells in patients with allergic diseases. J Allergy Clin Immunol 132(3):527–535CrossRefPubMed

Ding X, Cao H, Chen X, Jin H, Liu Z, Wang G, Cai L, Li D, Niu C, Tian H, Yang L, Zhao Y, Li W, Cui J (2015) Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. J Transl Med 13:158CrossRefPubMedPubMedCentral

Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E, Brandau S (2008) Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 59(1):32–40CrossRefPubMed

Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M et al (2016) Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. Oncoimmunology 6(1):e1163456CrossRefPubMedPubMedCentral

Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Münz C (2004) The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 172(3):1455–1462CrossRefPubMed

Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, Yamazaki H, Inoue H et al (2000) Clinical implications of interleukin-10 induced by non-small-cell lung cancer. Ann Oncol 11:815–819CrossRefPubMed

Hiraki A, Kiura K, Yamane H, Nogami N, Tabata M, Takigawa N, Ueoka H, Tanimoto M, Harada M (2002) Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer 35(3):329–333CrossRefPubMed

Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, Jersmann H, Hodge S (2014) Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin Exp Immunol 178(1):79–85CrossRefPubMedPubMedCentral

Huang AL, Liu SG, Qi WJ, Zhao YF, Li YM, Lei B, Sheng WJ, Shen H (2014) TGF-β1 protein expression in non-small cell lung cancers is correlated with prognosis. Asian Pac J Cancer Prev 15(19):8143–8147CrossRefPubMed

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2004) Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 83:1–1438PubMedCentral

Jin S, Deng Y, Hao JW, Li Y, Liu B, Yu Y, Shi FD, Zhou QH (2014) NK cell phenotypic modulation in lung cancer environment. PLoS One 9(10):e109976CrossRefPubMedPubMedCentral

Jonges LE, Albertsson P, van Vlierberghe RL, Ensink NG, Johansson BR, van de Velde CJ et al (2001) The phenotypic heterogeneity of human natural killer cells: presence of at least 48 different subsets in the peripheral blood. Scand J Immunol 53:103–110CrossRefPubMed

Kim S, Iizuka K, Aguila HL et al (2000) In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 97(6):2731–2736CrossRefPubMedPubMedCentral

Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G et al (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 10:3699–3707CrossRefPubMed

Li Yang L, Wang, Zhang Y (2016) Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 5(1):1–20PubMed

Lin M, Liang SZ, Wang XH et al (2017) Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res 65(4):880–887CrossRefPubMed

Lowry LE, Zehring WA (2017) Potentiation of natural killer cells for cancer immunotherapy: a review of literature. Front Immunol 8:1061CrossRefPubMedPubMedCentral

Loza MJ, Perussia B (2004) The IL‑12 signature: NK cell terminal CD56+ high stage and effector functions. J Immunol 172:88–96CrossRefPubMed

Lu LM, Zavitz CC, Chen B, Kianpour S, Wan Y, Stämpfli MR (2007) Cigarette smoke impairs NK cell-dependent tumor immune surveillance. J Immunol 178(2):936–943CrossRefPubMed

Luna JI, Grossenbacher SK, Murphy WJ, Canter RJ (2017) Targeting cancer stem cells with natural killer cell immunotherapy. Expert Opin Biol Ther 17(3):313–324CrossRefPubMed

Luppi P, Lain KY, Jeyabalan A, DeLoia JA (2007) The effects of cigarette smoking on circulating maternal leukocytes during pregnancy. Clin Immunol 122(2):214–219CrossRefPubMed

Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N, Raulet DH (2014) Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122:91–128CrossRefPubMedPubMedCentral

Mian MF, Lauzon NM, Stampfli MR, Mossman KL, Ashkar AA (2008) Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol 83:74–784CrossRef

Mian MF, Pek EA, Mossman KL, St€ampfli MR, Ashkar AA (2009a) Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I: C-augmented human PBMCs. Mol Immunol 46:3108e16

Mian MF, Pek EA, Mossman KL, Stampfli MR, Ashkar AA (2009b) Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I:C-augmented human PBMCs. Mol Immunol 46:3108–3116CrossRefPubMed

Mian MF, Steampfli MR, Mossman KL, Ashkar AA (2009c) Cigarette smoke attenuation of poly I: C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFNbeta production. Mol Immunol 46:825e9

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HE, Thompson JA et al (2017) A first-in-human phase 1 study of subcutaneous outpatient recombinant human IL-15 (rhIL-15) in adults with advanced solid tumors. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-17-2451

Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE et al (2015) Molecularly targeted therapies in non small cell lung cancer annual update 2014. J Thorac Oncol 10(101):S1–S63CrossRefPubMedPubMedCentral

Moszczyński P, Zabiński Z, Moszczyński P Jr, Rutowski J, Słowiński S, Tabarowski Z (2001) Immunological findings in cigarette smokers. Toxicol Lett 118(3):121–127CrossRefPubMed

Motz GT, Eppert BL, Wortham BW, Amos-Kroohs RM, Flury JL, Wesselkamper SC, Borchers MT (2010) Chronic cigarette smoke exposure primes NK cell activation in a mouse model of chronic obstructive pulmonary disease. J Immunol 184:4460–4469CrossRefPubMed

National Cancer Institute (2014) Surveillance, epidemiology and end results programme. Cancer stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed Nov 2017

Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL (2012) Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119(16):3734–3743CrossRefPubMedPubMedCentral

Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31(4):1076–1086CrossRefPubMed

Peter ME, Krammer PH (2003) The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10(1):26–35CrossRefPubMed

Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422CrossRefPubMed

Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126:458–465CrossRefPubMedPubMedCentral

Romee R et al (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease‑17 (ADAM17). Blood 121:3599–3608CrossRefPubMedPubMedCentral

Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, Schadendorf D, Hoffmann H, Umansky V (2011) Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 6(3):432–438CrossRefPubMed

Sopori M (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2(5):372–377CrossRefPubMed

Sopori ML, Gairola CC, DeLucia AJ, Bryant LR, Cherian S (1985) Immune responsiveness of monkeys exposed chronically to cigarette smoke. Clin Immunol Immunopathol 36(3):338CrossRefPubMed

Specht HM, Pelzel J, Hautmann H, Huber RM, Schossow B, Molls M, Multhoff G (2014) P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT)—clinical application of NK cells activated by heat shock protein 70 (Hsp70). J Immunother Cancer 2(Suppl 2):P41CrossRefPubMedCentral

Tonn T, Schwabe D, Klingemann HG et al (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15(12):1563–1570CrossRefPubMed

Villegas FR, Coca S, Villarrubia VG, Jime´nez R, Chillo´n MJ et al (2002) Prognostic significance of tumor infiltrating natural killer cells subset CD57 inpatients with squamous cell lung cancer. Lung Cancer 35:23–28CrossRefPubMed

Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44CrossRefPubMedPubMedCentral

World Health Organization (2012) International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed Nov 2017

Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, He J, Wu G, Liu X, Zhang Y (2015) Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 29(2):635–641CrossRefPubMed

Zhang G, Zhao H, Wu J, Li J, Xiang Y, Wang G, Wu L, Jiao S (2014) Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation. Int Immunopharmacol 21(2):396–405CrossRefPubMed

Titel: Role of natural killer cells in lung cancer
verfasst von: Ozge Nur Aktaş
Ayşe Bilge Öztürk
Baran Erman
Suat Erus
Serhan Tanju
Şükrü Dilege
Publikationsdatum: 03.04.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2635-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Role of natural killer cells in lung cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Combinational chromosomal aneuploidies and HPV status for prediction of head and neck squamous cell carcinoma prognosis in biopsies and cytological preparations

Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma

Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients’ prognosis

Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia

Impact of peri-operative blood transfusion on post-operative infections after radical gastrectomy for gastric cancer: a propensity score matching analysis focusing on the timing, amount of transfusion and role of leukocyte depletion

Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie